Antibody deficiency associated with gold treatment: Natural history and management in 22 patients

Annals of the Rheumatic Diseases

Volumn 55, Issue 9, 1996, Pages 616-621

  Snowden, N ^a   Dietch, D M ^a   Teh, L S ^a   Hilton, R C ^a   Haeney, M R ^a  

^a HOPE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AUROTHIOMALATE; IMMUNOGLOBULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNE DEFICIENCY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

EID: 0029791171     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.55.9.616     Document Type: Article

References (20)

1. Lorber A, Simon T, Leeb J, Peter A, Wilcox S. Chrysotherapy: suppression of immunoglobulin synthesis. Arthritis Rheum 1978;21:785-91.
2. So AKL, Peskett SA, Webster ADB. Hypogammaglobulinaemia associated with gold therapy. Ann Rheum Dis 1984;43:581-2.
3. Lee AH, Levinson AI, Schumacher HR. Hypogammaglobulinaemia and rheumatic disease. Semin Arthritis Rheum 1993;22:252-64.
4. Guillemin F, Bene M-C, Aussdat R, Bannwarth B, Pourel J. Hypogammaglobulinaemia associated with gold therapy: evidence for a partial maturation blockade of B cells. J Rheumatol 1987;14:1034-5.
5. Stanworth DR, Johns P, Williamson N, Shadforth M, Felix-Davies D, Thompson R. Drug-induced IgA deficiency in rheumatoid arthritis. Lancet 1977;i:1001-2.
6. Hunter T. Hypogammaglobulinaemia associated with gold therapy. Ann Rheum Dis 1985;44:212.
7. Olsen JC, Lovell DJ, Levinson JE. Hypogammaglobulinaemia associated with gold therapy in a patient with juvenile rheumatoid arthritis. J Rheumatol 1986;13:224-5.
8. Burns HJ, Klimiuk PS, Hilton RC, Haeney M. Gold-induced hypogammaglobulinaemia. Br J Rheumatol 1987; 26:53-5.
9. Jefferis R, Kumararatne DS. Selective IgG sub-class deficiency: quantification and clinical relevance. Clin Exp Immunol 1990;81:357-67.
10. Wheeler JG, Steiner D. Evaluation of humoral responsiveness in children. Pediatr Infect Dis J 1992;11:304-10.
11. Hazlewood M, Nusrat R, Kumararatne DS, Goodall M, Raykundalia C, Da Gong W, et al. The acquisition of antipneumococcal capsular polysaccharide, Haemophilus influenzae type b and tetanus toxoid antibodies, with age, in the UK. Clin Exp Immunol 1993;93:157-64.
12. Kumararatne DS, Bignall A, Joyce HJ, Hazlewoof M. Antibody deficiency disorders. In: Chapel HM, Gooi HC, eds. Clinical immunology: a practical approach. London: IRL press, 1990:1-22.
13. Bansal AS, Moran A, Potter M, Taylor R, Haeney MR, Mandal BK. Lymphocyte transformation responses to PHA and PWM in pateints at different stages of HIV infection: are they worth measuring? J Clin Pathol 1993;46:846-8.
14. ABPI data sheet compendium 1995-6. London: Datapharm, 1995.
15. British Society For Rheumatology. Guidelines for therapeutic drug monitoring. London: British Society for Rheumatology, 1995.
16. Farr M, Kitas GD, Tunn EJ, Bacon PA. Immunodeficiencies associated with sulphasalazine therapy in rheumatoid arthritis. Br J Rheumatol 1991;30:413-7.
17. Chapel HM (for the Consensus Panel for the Diagnosis and Management of Primary Antibody Deficiencies). Consensus on diagnosis and management of primary antibody deficiencies. BMJ 1994;308:581-5.
18. Pincus T, Callahan LF. Taking mortality in RA seriously: predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986;13:841-8.
19. Mitchell DM, Spitz PM, Young DY, Block DA, McShane DJ, Fries JF. Survival, prognosis and causes of death in RA. Arthritis Rheum 1986;29:706-14.
20. Shadick NA, Fanta CH, Weinblatt ME, O'Donnell W, Coblyn JS. Bronchiectasis: a late feature of severe rheumatoid arthritis. Medicine (Baltimore) 1994;73:161-70.